168,850 Shares in Accendra Health, Inc. $ACH Bought by State of Wyoming

State of Wyoming purchased a new position in Accendra Health, Inc. (NYSE:ACH) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 168,850 shares of the company’s stock, valued at approximately $385,000. State of Wyoming owned 0.22% of Accendra Health at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in shares of Accendra Health during the first quarter valued at about $5,943,000. Bank of New York Mellon Corp bought a new position in Accendra Health in the 1st quarter valued at about $592,000. Strs Ohio acquired a new position in Accendra Health during the 1st quarter valued at about $413,000. Allspring Global Investments Holdings LLC bought a new stake in Accendra Health during the 1st quarter worth approximately $239,000. Finally, Keybank National Association OH purchased a new stake in shares of Accendra Health in the first quarter worth approximately $46,000.

Accendra Health Stock Down 0.3%

NYSE ACH opened at $3.13 on Monday. The business has a 50-day simple moving average of $3.12. The company has a market capitalization of $239.70 million, a PE ratio of -0.22, a PEG ratio of 4.84 and a beta of 1.58. Accendra Health, Inc. has a 1 year low of $1.84 and a 1 year high of $7.99.

Accendra Health (NYSE:ACH) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $627.78 million for the quarter. Accendra Health had a negative return on equity of 13.18% and a negative net margin of 39.84%. As a group, equities analysts anticipate that Accendra Health, Inc. will post 0.31 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Zacks Research raised Accendra Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 21st. UBS Group increased their price target on Accendra Health from $3.00 to $4.50 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Robert W. Baird raised their price objective on Accendra Health from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Weiss Ratings raised Accendra Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, Citigroup dropped their price objective on Accendra Health from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Friday. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.00.

Accendra Health Profile

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.